Time-dependent ROC analysis of RRM2 expression in gliomas patients suggusted that RRM2 could well predict the prognosis of gliomas patients at 1, 3 and 5 years (Fig. 13C, D). The gene discussed is RRM2; the disease is central nervous system cancer.